Literature DB >> 3539231

Treatment of preleukemic syndromes with marrow transplantation.

F R Appelbaum, R Storb, R E Ramberg, H M Shulman, C D Buckner, R A Clift, H J Deeg, A Fefer, J Sanders, S Self.   

Abstract

Thirty patients with advanced preleukemic syndromes were treated with marrow transplantation. Most cases were diagnosed by the presence of peripheral pancytopenia and a diagnostic marrow examination but in 6 of the 30 patients pretransplant chromosome studies were instrumental in establishing the diagnosis. Three patients prepared for transplantation with cyclophosphamide alone recurred with their disease within 6 months of transplantation. The other 27 patients were treated with cyclophosphamide and total body irradiation. Twenty of these 27 patients had preleukemia not associated with prior therapy or severe marrow fibrosis. Thirteen of these 20 are alive and well 9 to 56 months from transplant and 7 died, 4 of interstitial pneumonia, 2 of candida septicemia, and 1 of disseminated zoster. There have been no disease recurrences in this group. The remaining preleukemic patients, which include 3 patients transplanted for preleukemia secondary to prior therapy and 4 patients transplanted for preleukemia associated with severe marrow fibrosis, have all died. Major problems in these patients included disease recurrence (2 cases) and, in those with severe marrow fibrosis, graft failure (2 cases). These results suggest that for patients with life-threatening pancytopenia due to spontaneous preleukemia without severe marrow fibrosis, marrow transplantation can prolong disease-free survival and may result in cure of the disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3539231

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.

Authors:  Betul Oran; Piyanuch Kongtim; Uday Popat; Marcos de Lima; Elias Jabbour; Xinyan Lu; Julien Chen; Gabriella Rondon; Partow Kebriaei; Sairah Ahmed; Borje Andersson; Amin Alousi; Stefan Ciurea; Elizabeth Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-20       Impact factor: 5.742

2.  Allogeneic and autologous bone-marrow transplantation.

Authors:  H J Deeg
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

3.  The myelodysplastic syndromes.

Authors:  E G Sims
Journal:  J Natl Med Assoc       Date:  1987-07       Impact factor: 1.798

4.  Future directions of bone marrow transplantation.

Authors:  N A Buskard
Journal:  CMAJ       Date:  1987-08-15       Impact factor: 8.262

5.  Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases.

Authors:  P Fenaux; J L Lai; J P Jouet; J P Pollet; F Bauters
Journal:  Blut       Date:  1988-11

Review 6.  Refractory anaemias.

Authors:  A K Saraya; P S Dhot; R Saxena
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

Review 7.  The iatrogenic leukaemias induced by radio- and/or chemotherapy.

Authors:  Y Najean
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

8.  Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Authors:  Hugo Castro-Malaspina; Ann A Jabubowski; Esperanza B Papadopoulos; Farid Boulad; James W Young; Nancy A Kernan; Miguel A Perales; Trudy N Small; Katharine Hsu; Michelle Chiu; Glenn Heller; Nancy H Collins; Suresh C Jhanwar; Marcel van den Brink; Stephen D Nimer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

Review 9.  Adverse haematological complications of anticancer drugs. Clinical presentation, management and avoidance.

Authors:  D C Bodensteiner; G C Doolittle
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

10.  Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.

Authors:  H Maschek; V Kaloutsi; M Rodriguez-Kaiser; M Werner; H Choritz; K Mainzer; M Dietzfelbinger; A Georgii
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.